Abstract:In recent years, the U.S. Food and Drug Administration (FDA) has approved Chimeric Antigen Receptor (CAR)-T cell therapy as a novel approach to treating hematological diseases, including multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukemia. Using the patient's genetically altered T-cells, this novel strategy precisely targets antigens linked to cancer. Even with the encouraging outcomes of using bi-specific chimeric antigen receptors to stop tumor antigen evasion, difficulties still arise, especially when dealing with solid tumors. There are several challenges because of the intricate interactions among many elements in the tumor microenvironment, such as immunosuppression, hypoxia, decreased T-cell infiltration, elevated reactive oxygen species, and the erratic nature of tumor-associated antigens. This study examines current efforts to find reliable tumor-associated antigens in an attempt to address issues impeding the efficacy of CAR-T treatment. The fundamental objective is to create CAR-T cells that are economical while being adapted to the distinct characteristics of the tumor microenvironment. By means of a comprehensive analysis of the course of the therapy, the study explores its potential therapeutic uses for a range of tumor types, including solid and hematological malignancies. This work not only sheds light on the enormous obstacles to obtaining precision medicine in cancer treatment, but it also advances our knowledge of the promise that the specific therapy has. The presented results open the door for future developments in the field and provide a nuanced viewpoint on the revolutionary role that the treatment has played in the contemporary cancer scene.

Advances and issues of CAR T cell therapy in B cell lymphoma

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR T-cell immunotherapy of B-cell malignancy: the story so far

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

The whole process management principles of chimeric antigen receptor T-cell therapy for lymphoma at Peking University Cancer Hospital

Recent advances in CAR T-cell therapy for lymphoma in China

Current progress in CAR-T cell therapy for tumor treatment

A long way to the battlefront: CAR T cell therapy against solid cancers.

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Advances in CAR-T-cell therapy in T-cell malignancies

From bench to bedside: the history and progress of CAR T cell therapy

Advances of CD19-directed Chimeric Antigen Receptor-Modified T Cells in Refractory/relapsed Acute Lymphoblastic Leukemia

The progress of CAR-T therapy in cancer and beyond

Current Clinical Application of the CAR-T Cell Therapy

Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors—a narrative review

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Updates in chimeric antigen receptor T-cell therapy for lymphoma

Current Progress in CAR-T Cell Therapy for Solid Tumors

Current state of CAR-T therapy for T-cell malignancies